Astellas (4503:JP) Non-Hormonal Therapy 'Veoza (Fezolinetant)' Receives European EC Approval
Emergence of an Innovative Non-Hormonal Therapy
On December 7, 2023, the European Commission (EC) formally approved Astellas Pharma’s Veoza (generic name Fezolinetant). The drug is the first non‑hormonal neurokinin‑3 (NK3) receptor antagonist indicated to alleviate moderate to severe vasomotor symptoms (VMS) associated with menopause. It received favorable regulatory assessment for offering a new therapeutic standard to the large population of women who cannot use or prefer to avoid hormone replacement therapy (HRT).
Demonstrated Efficacy and Safety in Phase 3 Trials
The approval was based on the global Phase 3 SKYLIGHT‑1 and SKYLIGHT‑2 studies, which enrolled approximately 3,000 patients. In the 45 mg dose group, the frequency of vasomotor symptoms (LS mean –2.53, p < 0.001) and severity (LS mean –0.29, p < 0.001) were significantly reduced versus placebo, demonstrating robust efficacy. The 52‑week SKYLIGHT‑4 extension evaluated long‑term safety and showed no increase in endometrial hyperplasia risk and confirmed a favorable tolerability profile, alleviating concerns about chronic use.
Differentiated Market Positioning and Competitive Landscape
The menopause symptom market is currently dominated by traditional hormone therapies and, to a lesser extent, selective serotonin reuptake inhibitors (SSRIs). However, patients with a history of breast cancer or cardiovascular risk have limited therapeutic options. Veoza provides a safe alternative for these hormone‑contraindicated populations and is pioneering a distinct non‑hormonal segment. A later entrant, Bayer’s dual NK1/NK3 receptor antagonist Elinzanetant (brand name Lynkuet), secured FDA approval in October 2025 and is aggressively pursuing market share, which is expected to intensify marketing competition to maintain leadership.
Market Size, Reimbursement, and Pricing Negotiation Challenges
The global menopause symptom market was estimated at approximately $4 billion in 2025 and is projected to expand to as much as $9 billion by 2035. Astellas has set Veoza’s peak global annual sales target at ¥150 billion to ¥250 billion, but the pace of initial prescribing and reimbursement uptake has been slower than anticipated, creating entry barriers. Pricing negotiations with European health authorities and demonstration of cost‑effectiveness will be decisive factors shaping future revenue growth.
Strategic Asset Acquisition and Future Growth Drivers
In 2017, Astellas acquired the Belgian company Ogeda for a total consideration of €800 million (including a €500 million upfront payment and €300 million in milestones), securing the core technology behind Veoza. This proactive venture M&A has now borne fruit, substantially contributing to pipeline diversification and mitigation of patent‑expiry risk. As regulatory approvals expand globally and prescribing data accumulate, the company anticipates a virtuous cycle that will generate additional R&D and commercial talent employment.
Veoza’s European approval establishes a non‑hormonal option in the roughly $4 billion global menopause symptom market, acting as a short‑term catalyst that positions Astellas with a new cash‑cow. The efficacy demonstrated in Phase 3 trials (SKYLIGHT 1 & 2) and the regulatory history, including the absence of an FDA Advisory Committee meeting, provide a mid‑ to long‑term benchmark for the clinical utility of NK3‑targeted therapies. Moreover, the emergence of Bayer’s Elinzanetant, approved in October 2025, creates a dual‑leader dynamic that will increase non‑hormonal market penetration and stimulate demand for R&D and marketing talent across the sector. Finally, Astellas’ €800 million acquisition of Ogeda (approximately $850 million) offers biotech investors a compelling exit benchmark for high‑value late‑stage asset M&A.
Source: EMA (ema)